Supertake
Illustration for GLP-1 Downstream Winners

GLP-1 Downstream Winners

James FD@jamesfoxdavies

+4.9%

since Sep 30

Practice

The idea

I believe GLP-1 drugs go from millions of patients to tens of millions over the next decade, and the money is made downstream of the drugmakers themselves. The anchor is the plumbing that wins regardless of which drug leads: injector components, glass, fill-finish capacity, and the distributors and telehealth platforms getting scripts to patients. Around that I hold a new-consumer layer, protein and fresh food, fitness, and changing wardrobes, since that side depends on how patients actually live over years, not a quarter.

What it owns

  • · , , , 28%
  • · , , , , , 25%
  • · , , , 19%
  • · , 13%
  • · , 8%
  • Cash7%